Latest Regulatory News

Anson Resources has gained regulatory approval to re-enter a historic well at its Green River Lithium Project, aiming to deepen the reservoir and advance its lithium resource definition. This move sets the stage for a critical feasibility study that could underpin future lithium production.

Tamboran Resources has completed a major stimulation campaign on its Shenandoah South well and raised US$55.4 million to fund further drilling, positioning itself to meet critical gas supply commitments in Australia’s Northern Territory.

Euro Manganese has successfully closed an oversubscribed Security Purchase Plan, raising A$1.5 million to advance its Chvaletice Manganese Project in the Czech Republic. The capital injection will support project development, strategic partnerships, and working capital needs.

Kincora Copper Limited reports a strategic pivot to a project generator model, unlocking over A$110 million in partner funding and advancing multiple copper-gold exploration projects across Australia and Mongolia.

Future Metals NL has announced a partially underwritten entitlement offer aiming to raise approximately AUD 2.64 million to support development of its Eileen Bore Project and working capital needs. The offer opens to eligible shareholders on 15 May 2025 and closes on 30 May 2025.

Paradigm Biopharmaceuticals has secured centralised US ethics approval for its pivotal Phase 3 trial of injectable pentosan polysulfate sodium (iPPS) targeting moderate to severe knee osteoarthritis, setting the stage for patient enrolment in Q3 2025.

MedAdvisor Limited has successfully closed its Share Purchase Plan, raising $2.668 million-exceeding its $2 million target-and plans an upcoming shareholder meeting to approve director share issuances.

PVW Resources reports promising assay results from its Capão Bonito rare earth project and expands exploration efforts across Brazil, bolstered by new metallurgical expertise.

Amplia Therapeutics reports a significant milestone in its ACCENT trial, with 15 confirmed partial responses indicating that narmafotinib combined with chemotherapy outperforms chemotherapy alone in advanced pancreatic cancer.

Euro Manganese Inc. reported a net loss of CAD 9.174 million for the half-year ending March 31, 2025, while making significant progress on its Chvaletice Manganese Project, including securing key permits and strategic status under EU and Czech frameworks. The company’s development hinges on completing a crucial private placement and share purchase plan to sustain operations.

Euro Manganese advances its Chvaletice manganese project with key regulatory approvals, leadership appointments, and a $9.8 million capital raise, while reporting a narrowed Q3 net loss.

Euro Manganese Inc. reported a $9.17 million net loss for the six months ending March 31, 2025, while advancing its Chvaletice Manganese Project and pursuing a critical $11.2 million capital raise. The company’s future hinges on successful financing and project milestones amid ongoing development costs.